THE US Food and Drug
Administration (FDA) has approved
a generic formulation of celecoxib,
Pfizer’s non-steroidal antiinflammatory
of the Cox-2 inhibitor
class, marketed as Celebrex.
In Australia the product is
indicated for short term pain relief
as well as a treatment for osteo and
rheumatoid arthritis.
Mylan Pharmaceuticals has
approval to market 50 mg
celecoxib capsules while Teva
Pharmaceuticals has won the
contract to supply higher doses.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jun 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jun 14
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.